A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis (REFINE)
Latest Information Update: 12 Jul 2024
At a glance
- Drugs Navitoclax (Primary) ; Ruxolitinib (Primary)
- Indications Myelofibrosis; Polycythaemia vera
- Focus Therapeutic Use
- Acronyms REFINE
- Sponsors AbbVie; AbbVie Germany
- 27 Jun 2024 Planned End Date changed from 2 Feb 2029 to 29 Jan 2025.
- 13 Dec 2022 Results(As of Feb 07, 2022: N = 32 of Cohort-3) investigating whether the type of Myelofibrosis correlated with clinical outcomes and responses suggestive of disease modification among JAKi treatment naive patients and risk presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 10 Dec 2022 Results (n=32) published in an AbbVie media release.